---
title: "Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294804192.md"
description: "Lipocine Inc. reported Q2 2026 results with revenue of $190,099, a 69.5% decline year-over-year, and a net loss of $(2.62) million. Diluted EPS was $(0.32). Revenue dropped due to lower licensing income, though TLANDO royalty revenue increased. The company executed major TLANDO licenses with Verity, SPC, Pharmalink, and Aché. Clinically, LPCN 1154 Phase 3 missed its primary endpoint, but post-hoc analysis showed potential efficacy. Capital raised via ATM supports operations through mid-2027."
datetime: "2026-08-04T10:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294804192.md)
  - [en](https://longbridge.com/en/news/294804192.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294804192.md)
generator: "portal-rs"
---

# Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary

Lipocine Inc. reported results for the quarter ended Q2 2026, with revenue of $190099 and a net loss attributable to common shareholders of $(2,622,595). Diluted loss per share was $(0.32), and revenue declined sharply versus the year‑ago quarter on lower licensing and other revenue mix.

**Financial Highlights**

-   Revenue: $190,099 for Q2 2026, down from $622,849 in Q2 2025 ( (69.5%) ).
-   Net income: Net loss attributable to common shareholders of $(2,622,595) for Q2 2026, versus $(2,205,716) in Q2 2025 (worse YoY).
-   Diluted EPS: $(0.32) for Q2 2026, compared with $(0.41) in Q2 2025.

**Business Highlights**

-   Revenue mix shifted toward royalty revenue from TLANDO; licensing revenue was down versus the prior year, affecting near‑term top‑line composition.
-   Clinical update: LPCN 1154 Phase 3 topline missed its primary endpoint; a post‑hoc analysis excluding one outlier site indicated potential efficacy.
-   Partnerships and licensing: Executed major TLANDO licenses with Verity, SPC, Pharmalink and Aché, creating a pipeline of milestones, royalties and commercial support.
-   Pipeline progress: Multiple programs across CNS, liver, obesity and maternal health advanced with Phase 1–3 activity, IND/PK studies and planned trials.
-   Liquidity: Capital raised via an ATM in 2026 increased cash resources to support operations and near‑term clinical activities through mid‑2027.

Original SEC Filing: Lipocine Inc. \[ LPCN \] - 10-Q - Aug. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LPCN.US](https://longbridge.com/en/quote/LPCN.US.md)

## Related News & Research

- [Lipocine 3Q 2026: Revenue $2.29M, EPS ($0.08) — 10-Q Summary](https://longbridge.com/en/news/304479448.md)
- [Lipocine Inc Q3 revenue surges on license and royalty income](https://longbridge.com/en/news/304463947.md)
- [KKR: ABF scaled to $91B as private IG and AI infrastructure expand the opportunity set](https://longbridge.com/en/news/304801277.md)
- [Visa (V) Just Gave Investors Something To Think About](https://longbridge.com/en/news/304838789.md)
- [Citi Downgraded Adobe Stock to Sell. I'd Buy It Now.](https://longbridge.com/en/news/304827167.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**